Skip to main content

Table 4 Kaplan-Meier median progression-free survival (PFS) and overall survival (OS) estimates for patients with and without early tumor shrinkage

From: Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer

   Early tumor shrinkage at 6 weeks p-value
<10 % ≥10 %
GEMOX PFS (months) median (95 % CI) 2.5 (1.7-3.2) 5.4 (2.0-8.9) 0.03
GEMOX plus erlotinib PFS (months) median (95 % CI) 1.3 (1.0-1.6) 8.3 (5.7-11.0) 0.00
Overall PFS (months) median (95 % CI) 2.1 (0.9-3.3) 7.3 (5.6-8.9) 0.00
   Early tumor shrinkage at 6 weeks p-value
<10 % ≥10 %
GEMOX OS (months) median (95 % CI) 4.8 (1.6-7.9) 9.5 (7.5-11.4) 0.03
GEMOX plus erlotinib OS (months) median (95 % CI) 6.4 (3.1-9.6) 11.4 (7.6-15.2) 0.00
Overall OS (months) median (95 % CI) 5.8 (3.0-8.5) 10.7 (8.9-12.6) 0.00